StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)

Research analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the stock.

Several other research analysts also recently issued reports on CANF. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Stock Performance

NYSE:CANF opened at $1.58 on Friday. The company has a market cap of $5.59 million, a price-to-earnings ratio of -0.88 and a beta of 1.36. The stock has a fifty day moving average price of $1.79 and a 200-day moving average price of $2.31. Can-Fite BioPharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.69.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC lifted its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.